CCM
CMPX icon

Coldstream Capital Management’s Compass Therapeutics CMPX Stock Holding History

Coldstream Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-879
Closed -$1.67K – 1573
2025
Q1 		$1.67K Buy
+879
New +$2.34K ﹤0.01% 3059

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Coldstream Capital Management's CMPX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 879 shares — an estimated $1.67K sold.

Coldstream Capital Management first reported a position in CMPX in Q1 2025 and held it in 1 quarter. The position peaked at $1.67K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 879 Compass Therapeutics shares in Q2 2025, an estimated $1.67K.
  • Coldstream Capital Management first reported a position in Compass Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Compass Therapeutics position peaked at $1.67K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.